<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054689</url>
  </required_header>
  <id_info>
    <org_study_id>11-091</org_study_id>
    <nct_id>NCT02054689</nct_id>
  </id_info>
  <brief_title>Fractionated Stereotactic Radiosurgery for Large Brain Metastases</brief_title>
  <official_title>PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research trial that seeks to break up the total radiation dose into multiple
      smaller radiation treatments, termed fractionated stereotactic radiosurgery (FSRS) which may
      make the treatment feasible. Fractionated sterotatcic radiation, the risks of FSRS, and
      possible costs will be described later in this document. This clinical trial is for people
      who have had no prior whole brain radiation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by any patients toxicities Performance status Quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of fractionated SRS</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by patient toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control of the disease</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Large Brain Mets</condition>
  <arm_group>
    <arm_group_label>Fractionated Stereotactic Radiosurgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>24 to 36 Gy in 3 fractions (8-12 Gy/fx).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fractionated Stereotactic Radiosurgery</intervention_name>
    <description>SRS SBRT CyberKnife Trilogy True Beam Radiosurgery</description>
    <arm_group_label>Fractionated Stereotactic Radiosurgery</arm_group_label>
    <other_name>SRS</other_name>
    <other_name>SBRT</other_name>
    <other_name>CyberKnife</other_name>
    <other_name>Trilogy</other_name>
    <other_name>True Beam</other_name>
    <other_name>Radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients â‰¥ 18 years of age

          -  A life expectancy of at least 12 weeks with a Karnofsky performance status of at least
             70 (Appendix II)

          -  The target lesion(s) can be accurately measured in at least one dimension according to
             RECIST

          -  No prior radiotherapy to the brain

          -  Previous or concurrent systemic or targeted chemotherapy is allowed.

          -  Patients must have an extra-cranial primary tumor diagnosis

          -  Patients will have no more than 3 distinct lesions within the brain.

          -  At least 1 lesion must be a minimum of 3cm in greatest dimension, no larger than 5cm
             which will be treatable by fractionated stereotactic radiosurgery

          -  The additional lesions will each be treated with single fraction stereotactic
             radiosurgery

          -  Patient may be on steroids or anti-epileptics

          -  Must be aware of the neoplastic nature of his/her disease and willingly provide
             written, informed consent after being informed of the procedure to be followed, the
             experimental nature of the therapy, alternatives, potential benefits, side-effects,
             risks and discomforts

          -  Patients do not need a histologically proven diagnosis of brain mets

        Exclusion Criteria:

          -  Symptomatic patients in need of surgery to the &quot;target&quot; lesion

          -  Four or more newly-diagnosed lesions

          -  Prior surgical resection of targeted tumor

          -  Prior WBRT

          -  Primary brain tumor

          -  Pregnant or breast-feeding patients

          -  Primary tumor histology of lymphoma, leukemia, multiple myeloma or germ cell tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight E Heron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen D Holeva, BS</last_name>
    <phone>412-623-1275</phone>
    <email>holevakd@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Shadyside Radiation Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen D Holeva, BS</last_name>
      <phone>412-623-1275</phone>
      <email>holevakd@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dwight E Heron, MD</last_name>
      <phone>412-623-6720</phone>
      <email>herond2@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Burton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Clump, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Flickinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johnathan Engh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nduka Amankulor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dwight E Heron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Dwight Heron</investigator_full_name>
    <investigator_title>Vice Chairman of Clinical Affairs</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

